Clinical Trials on Peritoneal Neoplasms in Argentina

Total 992 results

Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Renal Cell Carcinoma

France, Spain, Chile, United States, Argentina, Austria, Czechia, Greece, Italy, Mexico, Poland, Portugal, Romania, Russian Federation
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
Bristol-Myers Squibb

Completed

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

Pan Tumor

United States, Puerto Rico, Italy, Argentina, Australia, Belgium, Canada, Chile, Denmark, France, Germany, Netherlands, Poland, Romania, Singapore, Spain, United Kingdom
Pfizer
UCB Pharma

Terminated

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular

Belgium, United States, Canada, Hong Kong, Korea, Republic of, Portugal, Spain, Poland, India, Argentina, Italy, Mexico, Russian Federation, South Africa
Bristol-Myers Squibb
Astellas Pharma Inc; Clovis Oncology, Inc.

Active, not recruiting

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)

Prostate Cancer

United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Mexico, Spain
Antisoma Research

Unknown

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
Boehringer Ingelheim

Completed

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Russian Federation, South Africa, Spain, Sweden, Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD-3)

Renal Cell Carcinoma

Canada, United Kingdom, Hong Kong, Netherlands, United States, Thailand, Korea, Republic of, Spain, Australia, Denmark, Mexico, Germany, Turkey, Italy, France, Brazil, Peru, Taiwan, Argentina
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru
Eli Lilly and Company

Completed

A Phase III Trial For Patients With Metastatic Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer of the Breast

United States, Argentina, Australia, Brazil, Korea, Republic of, Mexico, Puerto Rico, Taiwan
Celltrion
Nippon Kayaku Co., Ltd.

Completed

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

HER2-positive Carcinoma of Breast

Italy, South Africa, Mexico, Japan, Taiwan, Russian Federation, Philippines, Hungary, Romania, Spain, Bosnia and Herzegovina, India, Peru, Ukraine, Latvia, Argentina, Georgia, Belarus, Chile, France, Poland, Portugal
GlaxoSmithKline

Completed

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

Italy, Argentina, Korea, Republic of, Estonia, Hong Kong, Ukraine, Ireland, Latvia, Pakistan, China, Austria, Greece, New Zealand, Poland, Russian Federation, United Kingdom, Australia, India, Czech Republic, Mexico, Brazil, Chile, ... and more
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Cushing's Disease

United States, Canada, Italy, Belgium, Turkey, Spain, France, Denmark, Germany, Greece, Israel, Argentina, China, Portugal, Brazil, Mexico, Finland, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

Triple Negative Breast Neoplasms

France, Italy, Croatia, Taiwan, Australia, Argentina, Korea, Republic of, China, Israel, Russian Federation, Slovakia, Slovenia, United Kingdom, Germany, Mexico, Switzerland, Spain, Brazil, Hungary, Malaysia, South Africa, Austria, ... and more
Pierre Fabre Medicament

Completed

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Breast Cancer

France, Poland, Ukraine, United Kingdom, Taiwan, Spain, Belgium, Belarus, Mexico, Bulgaria, India, South Africa, Brazil, Russian Federation, Argentina, Hungary, Italy, Serbia, Switzerland, Czechia, Estonia
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
Hoffmann-La Roche

Completed

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

Australia, Belgium, Germany, Hong Kong, Canada, Spain, Taiwan, Singapore, France, United Kingdom, Austria, Italy, Croatia, Serbia, Brazil, Israel, Lithuania, Poland, Greece, Argentina, Denmark, Romania, Mexico
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

China, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS)

Non-Small Cell Lung Cancer

Canada, Belgium, Brazil, China, Denmark, Portugal, Spain, United Kingdom, Argentina, Bulgaria, Colombia, Germany, India, Ireland, Italy, Luxembourg, Mexico, Poland, Romania, Slovakia, Switzerland, Vietnam, Kazakhstan, Czechia
Novartis Pharmaceuticals

Terminated

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

Non-Small-Cell Lung

Germany, Spain, Belgium, Canada, Netherlands, Italy, Taiwan, Argentina, Australia, Israel, Japan, Lebanon, France, Poland, United States, Jordan, Korea, Republic of, China, Brazil, Czechia, Greece, Russian Federation, Denmark, Hungary, ... and more
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States, Argentina, Brazil, Australia, Singapore, New Zealand, Russian Federation, Mexico, Peru, Chile
Bristol-Myers Squibb

Completed

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Melanoma

Australia, France, Italy, Poland, United Kingdom, United States, Spain, Belgium, Denmark, Germany, Norway, Switzerland, Argentina, Austria, Sweden, Czechia, Hungary, Netherlands, Mexico, Canada, Israel, South Africa
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
OSI Pharmaceuticals
Canadian Cancer Trials Group

Completed

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Carcinoma, Non-small-cell Lung

Canada, United States, Australia, Singapore, Israel, China, Argentina, Germany, Sweden, Brazil, Chile, Greece, Mexico, New Zealand, Romania, South Africa, Thailand
Advaxis, Inc.
Gynecologic Oncology Group

Terminated

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer (AIM2CERV)

High Risk Cervical Cancer | Advanced Cervical Cancer

United States, Argentina, Brazil, Canada, Chile, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Serbia, Spain, Taiwan, Ukraine
AstraZeneca
Parexel

Completed

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC (ASTRIS)

Lung Cancer

Canada, Denmark, Italy, Spain, Belgium, Korea, Republic of, Brazil, China, Taiwan, Australia, Austria, United Kingdom, Sweden, Argentina, Saudi Arabia, Ireland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma, Childhood and other conditions

United States, Italy, Japan, Germany, Spain, France, Canada, Australia, Brazil, Israel, Russian Federation, Argentina, United Kingdom, Finland, Belgium, Denmark, Czechia, Sweden, Switzerland, Netherlands
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Germany, Italy, Spain, United States, Hungary, Russian Federation, Poland, Belgium, Netherlands, France, Czechia, Mexico, Argentina, Canada, Denmark, Finland, Israel, Japan, Puerto Rico, United Kingdom
Sesen Bio, Inc.

Terminated

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Neoplasms, Squamous Cell | Mouth Neoplasms | Carcinoma, Squamous Cell of Head and Neck

Spain, Germany, Israel, Italy, Poland, United Kingdom, India, Argentina, France, Hungary, Serbia, Croatia, Ukraine, Brazil, Russian Federation, Mexico, Romania, Slovakia
Hoffmann-La Roche

Recruiting

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Breast Cancer

Korea, Republic of, United States, Israel, Denmark, Argentina, Mexico, Brazil, Germany, Peru, Poland, Spain, Taiwan, South Africa, Czechia, Italy, Australia, Hungary
Genzyme, a Sanofi Company

Completed

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Non-Small-Cell Lung Carcinoma

United States, France, Italy, Korea, Republic of, Peru, Spain, United Kingdom, Philippines, China, Germany, Hong Kong, Argentina, Austria, Canada, Israel, Taiwan, Mexico, Thailand, Belgium, Australia, Singapore, Netherlands
Boehringer Ingelheim

Completed

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Colorectal Neoplasms

United States, Argentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, T... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
Poniard Pharmaceuticals

Unknown

Study of Picoplatin Efficacy After Relapse (SPEAR)

Small Cell Lung Cancer

India, Russian Federation, Argentina, Belarus, Bosnia and Herzegovina, Bulgaria, Chile, Croatia, Hungary, Latvia, Montenegro, Poland, Romania, Serbia, Ukraine
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1)

Metastatic Breast Cancer

Spain, Taiwan, United States, Italy, Czechia, Germany, Belgium, Turkey, Brazil, Russian Federation, Argentina, Austria, France, Mexico
Deciphera Pharmaceuticals LLC

Active, not recruiting

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (INTRIGUE)

Gastrointestinal Stromal Tumors

United States, Korea, Republic of, Norway, Spain, Netherlands, Australia, Taiwan, France, United Kingdom, Belgium, Singapore, Canada, Italy, Poland, Sweden, Hungary, Germany, Israel, Czechia, Argentina, Chile, Switzerland
AstraZeneca

Active, not recruiting

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)

Biliary Tract Neoplasms

France, Italy, United States, Thailand, Korea, Republic of, United Kingdom, India, Japan, Poland, Russian Federation, Turkey, China, Taiwan, Hong Kong, Chile, Bulgaria, Argentina
Hoffmann-La Roche

Active, not recruiting

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib (ReAlec)

NSCLC

Belgium, Australia, China, Croatia, Finland, Turkey, Italy, Israel, Serbia, Austria, Romania, Peru, Lithuania, Colombia, Portugal, Czechia, Cuba, Russian Federation, Bulgaria, Vietnam, Uruguay, United Arab Emirates, Argentina, Chile, Pa...
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
AstraZeneca

Completed

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

Carcinoma, Non- Small Cell Lung

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
Hoffmann-La Roche

Completed

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (MODUL)

Colorectal Cancer

Italy, Korea, Republic of, United Kingdom, Belgium, Argentina, Denmark, Greece, Netherlands, Slovenia, Spain, Sweden, Turkey, Brazil, Bosnia and Herzegovina, France, Germany, Portugal, Egypt, Poland, Slovakia, Mexico, Serbia, Russian...
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Completed

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy (METIV-HCC)

Hepatocellular Carcinoma

United States, France, Italy, Germany, Spain, Switzerland, Belgium, Portugal, Netherlands, Australia, Brazil, Canada, Austria, New Zealand, Sweden, Argentina
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Ovarian Cancer

United States, France, Poland, United Kingdom, China, Belgium, Germany, Hong Kong, Taiwan, Spain, Canada, Netherlands, Sweden, Korea, Republic of, Singapore, Russian Federation, Argentina, Brazil, Chile, Australia
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
Merck KGaA, Darmstadt, Germany

Completed

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (EXPAND)

Gastric Cancer

Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, Germany, China, Hungary, Romania, Japan, Hong Kong, Argentina, Austria, Belgium, Chile, Israel, Greece, Taiwan, Au... and more
Hoffmann-La Roche

Terminated

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Gastric Cancer

United States, China, Korea, Republic of, Canada, Belgium, Brazil, Finland, Guatemala, Italy, Poland, Spain, Turkey, United Kingdom, Czechia, Hungary, Russian Federation, Argentina, France, Germany, Japan, Malaysia, Mexico, Panama, Peru, Philippin... and more
Pfizer

Completed

Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Belgium, Bulgaria, Hungary, Spain, Ukraine, Germany, Ireland, Korea, Republic of, Poland, Portugal, Russian Federation, Slovakia, Sweden, Mexico, Serbia, Singapore, Taiwan, Thailand, United Kingdom, Cyprus, Czech Republic, India, Ar... and more
Pfizer

Completed

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (INTORSECT)

Renal Cell Carcinoma

United States, Australia, Canada, Spain, France, Italy, Korea, Republic of, Denmark, Germany, United Kingdom, Singapore, Netherlands, Austria, Sweden, Chile, Argentina, China, Finland, Hungary, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE)

Breast Cancer

United States, South Africa, Austria, Hungary, Germany, Czechia, France, Russian Federation, Thailand, Belgium, Bulgaria, Lithuania, Jordan, Sweden, Finland, Peru, Colombia, Portugal, Canada, Brazil, India, Argentina, Costa Rica

Clinical Trials on Peritoneal Neoplasms in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations